IDIOPATHIC INFLAMMATORY MYOPATHY
Clinical trials for IDIOPATHIC INFLAMMATORY MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC INFLAMMATORY MYOPATHY trials appear
Sign up with your email to follow new studies for IDIOPATHIC INFLAMMATORY MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA injection aims to tame autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New injection aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Vivacta Biotechnology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug GT801 tested for tough autoimmune cases
Disease control Recruiting nowThis early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New biologic XmAb657 enters first human tests for autoimmune conditions
Disease control Recruiting nowThis early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Old drug, new hope: could filgotinib tame rare immune diseases?
Disease control Recruiting nowThis phase 2 trial is testing whether filgotinib, a drug already used for arthritis, can help people with three rare immune diseases: Behçet's disease, myositis, and IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term ster…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE2 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Tiny early trial launches for new autoimmune drug
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multip…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New injection aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests an injection called GT719 in 30 people with moderate to severe autoimmune diseases like lupus that haven't responded to standard treatments. The main goal is to check safety and find the right dose, while also looking at whether it helps control disea…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowThis phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Immune reset: CAR-T therapy targets lupus, MS, and more
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New RNA therapy aims to tame Out-of-Control immune system
Disease control Recruiting nowThis early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the dise…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on lupus and scleroderma in new trial
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control Recruiting nowThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental CAR-T therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells take on autoimmune diseases in early trial
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental CAR-T therapy takes on lupus and more
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Researchers launch major study to unravel mysteries of muscle disease
Knowledge-focused Recruiting nowThis study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 children and adults with myositis, along with healthy volunteers, to track changes in the immune system and other health problems over…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New study aims to unlock secrets of rare muscle disease
Knowledge-focused Recruiting nowThis study is building a library of information and samples from 60 adults with suspected autoimmune myopathy, a rare muscle disease. Researchers will collect blood, urine, stool, and muscle tissue, along with medical data, to better understand the condition. The goal is to impro…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Blood and AI join forces to catch lung scarring early in rheumatic disease patients
Knowledge-focused Recruiting nowThis study aims to find better ways to detect lung scarring (interstitial lung disease) early in people with connective tissue diseases like scleroderma or rheumatoid arthritis. Researchers will analyze tiny particles in the blood called extracellular vesicles and use AI to exami…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Patients take the lead: rare myositis study puts your voice first
Knowledge-focused Recruiting nowThis study asks 700 people with rare myositis diseases (and their caregivers) what research questions matter most to them. Through online surveys and forums, the goal is to create a patient-driven list of priorities to guide future studies and funding. No drugs or treatments are …
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Sponsor: Myositis International Health & Research Collaborative Alliance Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC